当前位置:首页 - 行情中心 - 恒瑞医药(600276) - 财务分析 - 现金流量表

恒瑞医药

(600276)

  

流通市值:3057.46亿  总市值:3181.21亿
流通股本:63.79亿   总股本:66.37亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金24,947,126,187.2913,442,616,615.046,671,724,436.3633,605,876,222.74
  收到其他与经营活动有关的现金1,354,944,275.83914,541,634.64252,626,908.491,228,283,666.84
  经营活动现金流入小计26,302,070,463.1214,357,158,249.686,924,351,344.8534,834,159,889.58
  购买商品、接受劳务支付的现金1,440,990,266.63809,768,240.91379,189,175.22,099,963,151.92
  支付给职工以及为职工支付的现金5,864,348,043.764,028,999,278.742,166,754,419.697,004,960,838.62
  支付的各项税费2,209,484,418.741,549,705,077.79698,501,493.042,787,135,744.23
  支付其他与经营活动有关的现金8,943,597,604.585,981,681,779.92,893,460,356.2111,706,722,024.18
  经营活动现金流出小计18,458,420,333.7112,370,154,377.346,137,905,444.1423,598,781,758.95
  经营活动产生的现金流量净额7,843,650,129.411,987,003,872.34786,445,900.7111,235,378,130.63
二、投资活动产生的现金流量:
  收回投资收到的现金---151,000,000
  取得投资收益收到的现金35,082,458.915,678,236.94518,588.5151,492,129.44
  处置固定资产、无形资产和其他长期资产收回的现金净额123,049,201.4452,528,697.1510,854,350.5518,911,785.27
  投资活动现金流入小计158,131,660.3468,206,934.0911,372,939.06221,403,914.71
  购建固定资产、无形资产和其他长期资产支付的现金2,670,616,430.061,577,505,322.86704,818,964.872,961,906,284.58
  投资支付的现金315,300,000315,300,00030,300,000-
  投资活动现金流出小计2,985,916,430.061,892,805,322.86735,118,964.872,961,906,284.58
  投资活动产生的现金流量净额-2,827,784,769.72-1,824,598,388.77-723,746,025.81-2,740,502,369.87
三、筹资活动产生的现金流量:
  吸收投资收到的现金---10,351,937,892.28
  取得借款收到的现金1,844,676,131.051,491,095,462.51299,534,222.251,495,572,622.12
  收到其他与筹资活动有关的现金---418,168,545
  筹资活动现金流入小计1,844,676,131.051,491,095,462.51299,534,222.2512,265,679,059.4
  偿还债务支付的现金1,493,174,9551,493,174,955300,000,0001,500,000,000
  分配股利、利润或偿付利息支付的现金1,328,140,177.291,328,140,177.29-1,284,255,700.45
  支付其他与筹资活动有关的现金459,907,568.17259,566,906.03185,251,178.591,699,715,987.25
  筹资活动现金流出小计3,281,222,700.463,080,882,038.32485,251,178.594,483,971,687.7
  筹资活动产生的现金流量净额-1,436,546,569.41-1,589,786,575.81-185,716,956.347,781,707,371.7
四、汇率变动对现金及现金等价物的影响-939,738,909.26-696,646,671.36-349,701,516.56-360,132,552.71
五、现金及现金等价物净增加额2,639,579,881.02-2,124,027,763.6-472,718,59815,916,450,579.75
  加:期初现金及现金等价物余额40,155,552,697.4140,155,552,697.4140,155,552,697.4124,239,102,117.66
  期末现金及现金等价物余额42,795,132,578.4338,031,524,933.8139,682,834,099.4140,155,552,697.41
补充资料:
  净利润-4,465,282,419.88-7,717,002,245.78
  资产减值准备-18,334,072.43-86,914,039.97
  固定资产和投资性房地产折旧-396,210,578.75-689,203,837.11
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-396,210,578.75-689,203,837.11
  无形资产摊销-91,168,178.35-114,581,839.37
  长期待摊费用摊销-32,655,550.32-97,702,799.02
  处置固定资产、无形资产和其他长期资产的损失--40,624,532.98--4,053,134.77
  固定资产报废损失-5,500,257.83-3,289,843.5
  公允价值变动损失--843,222,978.34--173,573,838.21
  财务费用-668,524,563.32-374,481,650.12
  投资损失-56,444,685.47-57,480,679.6
  递延所得税-151,624,594.49--403,931,406.24
  其中:递延所得税资产减少--6,812,004.91--403,782,268.44
    递延所得税负债增加-158,436,599.4--149,137.8
  存货的减少--133,892,624.92--479,237,472.88
  经营性应收项目的减少--766,018,031.54--1,097,175,061.93
  经营性应付项目的增加--2,309,045,675.46-4,134,810,119.38
  其他-180,307,909.1-53,018,404.41
  现金的期末余额-38,031,524,933.81-40,155,552,697.41
  减:现金的期初余额-40,155,552,697.41-24,239,102,117.66
  现金及现金等价物的净增加额--2,124,027,763.6-15,916,450,579.75
公告日期2026-10-282026-08-202026-04-232026-03-26
审计意见(境内)标准无保留意见
TOP↑